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Diversity of Amyloid-beta 
Proteoforms in the Alzheimer’s 
Disease Brain
Norelle C. Wildburger  1, Thomas J. Esparza1, Richard D. LeDuc  2, Ryan T. Fellers2,  
Paul M. Thomas  2, Nigel J. Cairns1,3,4,5, Neil L. Kelleher  2,6,7, Randall J. Bateman1,3,5 &  
David L. Brody1,5
Amyloid-beta (Aβ) plays a key role in the pathogenesis of Alzheimer’s disease (AD), but little is known 
about the proteoforms present in AD brain. We used high-resolution mass spectrometry to analyze 
intact Aβ from soluble aggregates and insoluble material in brains of six cases with severe dementia and 
pathologically confirmed AD. The soluble aggregates are especially relevant because they are believed 
to be the most toxic form of Aβ. We found a diversity of Aβ peptides, with 26 unique proteoforms 
including various N- and C-terminal truncations. N- and C-terminal truncations comprised 73% and 
30%, respectively, of the total Aβ proteoforms detected. The Aβ proteoforms segregated between the 
soluble and more insoluble aggregates with N-terminal truncations predominating in the insoluble 
material and C- terminal truncations segregating into the soluble aggregates. In contrast, canonical 
Aβ comprised the minority of the identified proteoforms (15.3%) and did not distinguish between the 
soluble and more insoluble aggregates. The relative abundance of many truncated Aβ proteoforms 
did not correlate with post-mortem interval, suggesting they are not artefacts. This heterogeneity of 
Aβ proteoforms deepens our understanding of AD and offers many new avenues for investigation into 
pathological mechanisms of the disease, with implications for therapeutic development.
Aβ has been the major target for disease-modifying therapeutic development in AD, driven in large part by 
studies of Down syndrome and studies of autosomal dominant AD and sporadic, late-onset AD, which implicate 
increased production, decreased clearance, and Aβ aggregation1, 2. However, little is known about the proteoforms 
(i.e., all protein variants of a single gene including post-translational modifications and sequence variants)3 of Aβ 
in human AD brain. Previous studies have demonstrated some sequence heterogeneity and post-translational 
modifications (PTMs) of the Aβ peptide in amyloid-beta plaques4–9. Yet amyloid-beta plaques, one of the patho-
logical hallmark of AD, correlate only moderately with dementia10–12. As a result, focus has shifted in recent years 
to the most toxic forms of Aβ, soluble aggregates previously termed ‘oligomers’ and other appellations13, as they 
demonstrate a strong correlation with dementia14–19.
Toward this end, we used high-resolution mass spectrometry to obtain highly accurate measurements and 
peptide-sequencing information of intact, undigested Aβ from soluble and insoluble Aβ aggregates isolated from 
human AD brain (Table 1). Soluble Aβ aggregates were isolated with our fully quantitative, sensitive, specific, and 
efficient purification strategy20 (Fig. 1). For comparison, more insoluble Aβ aggregates were analyzed from the 
same brain samples. Analysis of undigested (i.e., top-down proteomics) peptides by nano-liquid chromatography 
tandem mass spectrometry (nLC-MS/MS) allows unambiguous identification of Aβ and fully characterizes the 
composition of individual proteoforms. The advantages of nLC-MS/MS over other techniques like matrix-assisted 
laser desorption/ionization (MALDI) include: i) chromatographic separation of various proteoforms before mass 
1Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO, 
63110, United States. 2Proteomics Center of Excellence, Northwestern University, Evanston, IL, United States. 
3Department of Neurology, Knight Alzheimer’s Disease Research Center, 4488 Forest Park Pkwy, St. Louis, MO, 
63112, United States. 4Department of Pathology and Immunology, 660 South Euclid Avenue, St. Louis, MO, 63110, 
United States. 5Department of Neurology, Hope Center for Neurological Disorders, 660 South Euclid Avenue, St. 
Louis, MO, 63110, United States. 6Department of Molecular Biosciences, Northwestern University, Evanston, IL, 
United States. 7Department of Chemistry, Northwestern University, Evanston, IL, United States. Correspondence 
and requests for materials should be addressed to N.C.W. (email: n.wildburger@wustl.edu) or D.L.B. (email: 
brodyd@neuro.wustl.edu)
Received: 26 May 2017
Accepted: 8 August 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific REPORTS | 7: 9520  | DOI:10.1038/s41598-017-10422-x
spectrometry analysis, which offers better sample separation to effectively reduce sample complexity and improve 
resolution, ii) higher mass accuracy for the intact proteoforms, and iii) identification of fragment ions from direct 
de novo sequencing. Purification of soluble Aβ aggregates from frozen human AD brain by differential ultra-
centrifugation and immunoprecipitation resulted in ~10,000-fold enrichment and ~60% recovery of starting 
material20. Even so, Aβ comprised approximately 0.1% of the total protein content of the soluble high molecular 
weight (HMW) aggregates (Supplementary Table 1), requiring further enrichment before mass spectrometry 
analysis. We achieved substantial additional separation of Aβ from the other, as-yet-uncharacterized protein 
components of the soluble Aβ aggregates through an optimized C8 solid phase extraction protocol adaptable 
to varying amounts of total Aβ input (Supplementary Fig. 1; Supplementary Table 2). Using these methods, we 
analyzed Aβ extracted from brain tissue of six cases of AD each of whom had clinically severe AD dementia at 
expiration in an untargeted mass spectrometry approach (Supplementary Figs 2–4).
We identified 26 Aβ proteoforms in AD brain (Fig. 2). The proteoforms were identified with a high degree 
of mass accuracy, as were fragment ions that allowed unambiguous determination of their primary structures 
(Fig. 3, Supplementary Fig. 5). Contained within our dataset were numerous forms of Aβ with N-terminal 
truncations (Aβx-40/42), C-terminal truncations (Aβ1-x), and in one case (Aβ11-34), both N- and C-terminal 
truncations (Fig. 2). The canonical forms of Aβ traditionally studied, Aβ1–42 and Aβ1–40, were present through-
out all participants in all fractions. Aβ1–42, in both its oxidized and un-oxidized forms had one of the highest 
relative abundances in the mass spectrometry datasets. Aβ1–40 was also abundant, but with more variability 
amongst participants in both fractions, particularly in its oxidized form. Interestingly, no Aβ1–38, or any 38- or 
37-terminating proteoforms, were identified in our dataset even though this species is commonly detected in 
cerebrospinal fluid (CSF)21, 22.
The N-terminal truncations identified include Aβ2-x, Aβ3-x, Aβ4-x, Aβ5-x, Aβ8-x, and Aβ11-x. C-terminal 
truncated forms of Aβ include Aβx-20, Aβx-31, and Aβx-34 (Fig. 2A). The most frequent start and end positions 
were at 1 (D; aspartic acid) and 42 (A; alanine), respectively (Fig. 2B,C), like canonical Aβ1–42. However closer 
inspection revealed that the most frequent proteoform length was 40 amino acids followed by 32 (Fig. 2D) and 
not a full 42 amino acid sequence. Only 4 out of 26 proteoforms were full-length (15.3%). The heterogeneity in 
sequence length can be largely attributed to the N-terminal heterogeneity (Fig. 2B) as 19 out of the 26 (73%) 
proteoforms contained N-terminal truncations as has been previously observed22, 23. While less frequent by com-
parison, 8 out of 26 (30%) proteoforms contained C-terminal truncations. Overall, the majority of proteoform 
sequences terminated at alanine 42 (18 out of 26, 69.2%; Fig. 2C) compared to 9.5% terminating in valine 40 (4 out 
of 26) in keeping with previous studies demonstrating that Aβx-42 aggregation rates were higher in amyloidosis24. 
Traditionally used Aβ1–40, Aβ1–42, or Aβ1-x (i.e., canonical N-terminus) enzyme-linked immunosorbent assays 
(ELISAs) would not detect the majority of these forms, which fits well with our previous report that much of the 
Aβ measured by ELISA in human brain interstitial fluid is neither Aβ1–40 nor Aβ1–4221.
The post-translationally modified forms of Aβ comprised N-terminal pyro-glutamate, oxidation of methio-
nine, and in one instance an ammonium ion adduct at the C-terminus, which to our knowledge has not been 
Pt No. Status Age, yr PMI, hr Gender
1 CDR 3 73 12 male
2 CDR 3 83 6.3 female
3 CDR 3 92 18 female
4 CDR 3 86 15.5 female
5 CDR 3 89 6 female
6 CDR 3 82 10.75 male
Table 1. Characteristics of Human Brain Frontal Cortex Samples.
Figure 1. Isolation and comparison of Aβ proteoforms from human AD brain. Workflow for isolation of 
endogenous Aβ proteoforms. Cortical tissue was dounce homogenized with sub-critical micelle concentration 
of CHAPS followed by differential ultracentrifugation, anti-Aβ dual antibody immunoprecipitation, and elution 
in neat formic acid. Immunoprecipitated Aβ proteoforms in the HMW soluble aggregates fractions and more 
insoluble fractions were precipitated and purified from undigested non-Aβ proteins using C8 TopTips and 
analyzed by nLC-MS/MS. RCF, relative centrifugal force; Sol., soluble; LMW, low molecular weight; HMW, high 
molecular weight; IP, immunoprecipitation; pptn., precipitation; SPE, solid phase extraction.
www.nature.com/scientificreports/
3Scientific REPORTS | 7: 9520  | DOI:10.1038/s41598-017-10422-x
previously reported. No reagents in our isolation protocol contained ammonia. Many of the other forms, includ-
ing pyro-glutamate modification of amino acid 11 and truncated Aβ4–42, were of high relative abundance sim-
ilar to canonical Aβ1–42. One caveat to cross-proteoform comparison is that the relative abundance in the mass 
spectrometry datasets is largely dependent on the ionization efficiency of various Aβ proteoforms. The ionization 
efficiency can be altered by sequence truncations and/or PTMs. Thus, the most reliable quantitative comparisons 
can only be made for a given proteoform between patients or fractions in this study.
Differential mass spectrometry (dMS) analysis revealed no statistically significant differences in Aβ pro-
teoform abundance of the 26 Aβ proteoforms identified using two independent platforms, between soluble 
aggregates and the more insoluble material (Fig. 4; Supplementary Table 3)25. However, it did uncover trends in 
regard to the types of proteoforms in each fraction. N-terminally truncated proteoforms, where the hydrophilic 
region of the peptide is removed leaving the mid-domain and hydrophobic C-terminus, were more enriched in 
the insoluble fraction relative to the soluble aggregates26. In contrast, enriched species in the soluble Aβ aggregate 
fraction were proteoforms with nearly the entire hydrophobic C-terminus truncated. One proteoform, Aβ11–34, 
contained both N- and C-terminal truncations, which has not been described previously. Aβ1–34 was 5.6-fold 
more abundant in the soluble aggregates fraction than in the more insoluble material (Fig. 4, Supplementary 
Fig. 6). Aβ1–20 and Aβ11–34, both previously reported in the CSF22, 27, were 4- and 2.9-fold more abundant in 
the more soluble material, respectively (Supplementary Figs 7 and 8). Notably, Aβ1–42 and Aβ1–40 appeared to 
be the least significantly differentially expressed between the two fractions, remaining well within the ±2-fold 
change threshold (Fig. 4).
Next we sought to determine if the post-mortem interval (PMI) could affect Aβ proteoform truncations and 
PTMs (Supplementary Fig. 9). The signal intensity (i.e., relative abundance) of Aβ2–42 and Aβ3–42 showed a 
negative correlation in the soluble aggregates as a function of PMI and no significant effect in the more insoluble 
aggregates. This is the opposite of the increase that would be expected if these truncations were an artefact of PMI. 
Figure 2. Heterogeneity of Aβ proteoforms in the human Alzheimer’s disease brain. (A) Top: full protein 
sequence of amyloid precursor protein with Aβ1–42 sequence highlighted (grey). Left: Identified Aβ 
proteoform sequence names, with blue bars representing the alignment with canonical Aβ. Right: Heatmap 
and quantification of the log2 relative intensity of each Aβ proteoform for each of the six severe Alzheimer’s 
disease brain samples in the soluble aggregate and more insoluble fractions. Far right: Peptide score, indicated 
confidence of peptide identification38. (B) Frequency of Aβ proteoform amino acid start positions identified 
in CDR3 cohort; 1 = D, aspartic acid. (C) Frequency of Aβ proteoform amino acid end positions identified 
in CDR3 cohort; 42 = A, alanine. (D) Frequency of Aβ proteoform lengths identified in CDR3 cohort. Pt., 
Participant; HMW, high molecular weight; N.D., not detected; Ox., Oxidation; Pyro., Pyro-glutamate; Amm., 
ammonium ion.
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The N-terminal truncations Aβ4–42, Aβ4–40, Aβ5–42 Amm., Aβ5–42, Aβ8–42, and Aβ8–40 all demonstrated no 
significant correlation with PMI in either the soluble or more insoluble aggregates (Supplementary Fig. 9N-U). 
The C-terminally truncated proteoforms found with high relative expression in the soluble aggregates – Aβ1–
34, Aβ1–20, and Aβ11–34 – demonstrated no significant correlation with PMI (Supplementary Fig. 9A,G,V). 
Proteoform Aβ1–31 also showed no significant correlation. Intriguingly, the truncated proteoform Aβ11–42, in 
both the un-oxidized and oxidized state, and as well as Aβ p11–42 showed a high positive correlation in the more 
insoluble aggregates with PMI, but a high to moderate negative trend in the soluble aggregates (Supplementary 
Fig. 9Y,Z). Given that the trend for increased relative abundance of Aβ11–42 occurs irrespective of the oxidation 
status of methionine 35, we postulate that this may be due to the N-terminal truncation rather than oxidation. 
This may reflect residual BACE1 activity in the brain even after death28 for which neither our standard inhibitors 
(aprotinin and leupeptin) nor the protease cocktail, would block or inactivate (Supplementary Fig. 2). However, 
these results should be interpreted with caution due to the small sample size; only two participants had PMI 
of ≥12 hours.
To summarize, we have demonstrated that human brain soluble Aβ aggregates consist of an extraordinarily 
heterogeneous population of Aβ proteoforms. Other human brain proteins such as alpha-synuclein have not 
been reported to contain such substantial heterogeneity29, though tau post-translational modifications are pro-
tean in transgenic mouse brains30. Our results provide the first direct information regarding the proteoform 
constituents of soluble Aβ aggregates in human AD brain of which we are aware. Soluble Aβ aggregates may be 
important therapeutic targets, as they are believed to be the most toxic form of Aβ. Notably, human brain soluble 
Aβ aggregates have been reported to be substantially more toxic than similarly sized synthetic Aβ aggregates31, 32. 
These results suggest the hypothesis that previously unrecognized Aβ proteoforms may contribute to the modu-
lation of aggregate toxicity in AD. However, these results should be interpreted with caution as some of these Aβ 
proteoforms have also been detected in cognitively intact individuals with Aβ and tau pathology33. The lack of 
control (i.e., unaffected) samples in this study limits the interpretation of these findings. The specificity of these 
Aβ proteoforms cannot be determined through comparison to similarly prepared non-AD brain or early stage 
AD samples. Clearly, a great deal of additional investigation with a larger cohort will be required to determine 
the clinical relevance, aggregation properties, and toxicity of the Aβ proteoforms described here. Cross-sectional 
study of Aβ proteoforms to map disease specificity (control versus AD), disease progression specificity (control 
Figure 3. Mass spectrometry of Aβ proteoforms from human AD brain. (A) nano-Liquid chromatography-
tandem mass spectrometry (nLC-MS/MS) spectrum for undigested, full-length Aβp11–42. Each peak 
represents an ion fragmented from Aβp11–42, with peaks labeled ‘b’ representing N-terminal fragment ions 
and peaks labeled ‘y’ representing C-terminal fragment ions. The numbers indicate measured mass-charge 
ratio (m/z). The single letter amino acid code across the top indicates the de novo sequence identified by mass 
spectrometry, which matches the amyloid precursor protein sequence corresponding to Aβp11–42. The line 
breaks between amino acids indicate a cleavage of the amide bond between two adjacent amino acids producing 
fragment ions. The lines below each amino acid indicate a detected ‘b’ ion, and lines above indicate a detected 
‘y’ ion. Inset: isotopic envelope for the +4 charged, full-length Aβp11–42; the peaks are spaced 0.25 daltons 
apart at z = +4 because the naturally occurring isotopes (e.g. 13C and 15N) differ by 1 dalton. For the +4 ion, the 
observed m/z was 829.9551 (theoretical m/z = 829.9523), which was 3.4 parts-per-million (ppm) error from 
the theoretical mass of Aβp11–42. (B) Spectrum for full length Aβ4–42. For the +5 ion, the observed m/z was 
840.2427 (theoretical m/z = 840.2399), which was 3.3 ppm error from the theoretical mass of Aβ4–42.
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versus mild versus severe AD) is the next logical step, as this will inform future efforts in animal models of the 
disease. The extent to which the most relevant Aβ proteoforms are recapitulated in animal models of AD-related 
pathology remains to be determined and may be of great importance for preclinical therapeutic development.
Methods and Materials
Regulatory Compliance. All protocols were carried out in accordance with the Charles F. and Joanne 
Knight Alzheimer’s Disease Research Center and Washington University guidelines. This specific study was 
approved by the Knight Alzheimer’s Disease Research Center tissue committee. All donors or their surrogates 
gave informed consent for their brains to be used for research studies.
Human Tissue. Clinically and neuropathologically well-characterized human brain tissue samples 
were obtained from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center (knight ADRC), 
Washington University School of Medicine, Saint Louis, Missouri. At the time of death, informed consent was 
obtained from the next of kin in accordance with the local Institutional Review Board. Cognitive status at expi-
ration was determined using a validated retrospective post-mortem interview with an informant to establish the 
Clinical Dementia Rating (CDR)34. We used frozen tissue from the frontal lobe (Brodmann areas 8/9) of severely 
demented participants with Alzheimer’s disease dementia (CDR3, mean age at death = 84 ± 6.6 yrs; n = 6; mean 
post-mortem interval = 11.4 ± 4.8 hours (Table 1). In addition, parietal lobe was used for method development 
in addition to frontal lobe. Routinely, the right cerebral hemisphere was coronally sliced at 1 cm intervals and 
frozen by contact with pre-cooled Teflon®-coated aluminum plates and temperature equilibrated by immersion 
into liquid nitrogen vapor in a cryo-vessel. Following freezing, tissues were placed in Ziploc® storage bags and 
stored in freezer at −80 °C35.
Amyloid-beta (Aβ) Extraction and Separation of Soluble Aggregates from Insoluble 
Material. Complete methods are described in Esparza et al.20. Briefly, 1–2 g of frozen CDR3 (severe AD) 
frontal cortical samples, including both gray and white matter, were weighed, stripped of pia mater, leptome-
ningeal, and intraparenchymal vessels to the fullest extent possible. and dounce homogenized at a 10:1 buffer 
volume:tissue weight ratio using a constant 25–40 manual strokes. Homogenization buffer consisted of ice-cold 
1X phosphate buffered saline (PBS) (137 mM sodium chloride, 7.76 mM sodium phosphate dibasic, 2.17 mM 
monopotassium phosphate, 2.7 mM potassium chloride) with 0.45% (w/v) (3-((3-cholamidopropyl) dimethylam-
monio)−1-propanesulfonate) (CHAPS) and 1X protease inhibitor (2 ug/mL aprotinin and 1 ug/mL leupeptin). 
The resulting homogenate was rotated for 15 min at 4 °C before centrifugation at 17,000 × g for 30 min in a Sorvall 
RC 5B centrifuge with a SS-34 rotor. The supernatant was centrifuged in Beckman Optima XPN-100 centrifuge 
with a Ti70.1 rotor for 60 min at 100,000 × g at 4 °C, and the pellet (insoluble material; see below) was resolubilized 
in 5 M guanidine hydrochloride. The supernatant of the 100,000 x g spin was centrifuged for 60 min at 475,000 × g 
at 4 °C with a 70% sucrose cushion. The bottom layers (~2 mL) atop of the sucrose cushion (see Fig. 1a) were used 
for analysis of soluble Aβ aggregates. These methods have been demonstrated to preserve the size distribution of 
soluble Aβ aggregates present in PBS lysates, and do not result in artefactual aggregation of monomeric Aβ20. All 
pipet tips and tubes were blocked with 2% bovine serum albumin to significantly reduce non-specific loss of Aβ.
Purification of Soluble Aβ Aggregates. The layers atop the 70% sucrose cushion of the 475,000 × g spin 
were immunoprecipitated with 100 uL/mL of a 50% slurry of beads conjugated to the monoclonal antibodies 
HJ3.4 and HJ5.1 overnight (22 hrs) at 4 °C. HJ3.4 binds the N-terminus of canonical Aβ, and HJ5.1 binds a 
mid-domain epitope. Beads were washed 15 times in (1 mL each) 1X PBS and eluted with formic acid at room 
Figure 4. Determination of significant differentially expressed Aβ proteoforms. Logarithmic ratios of soluble 
versus insoluble fractions are plotted against the negative logarithmic q-values (q is a false discovery rate 
corrected p-value, where q ≤ 0.05 is considered statistically significant; above horizontal line) of the hierarchical 
linear model with replicates nested within participants and participants treated as random effects to test the 
fixed effect difference between soluble and insoluble aggregates. Vertical lines designate the logarithmic ratio 
indicating ±2-fold change. All Aβ proteoforms are listed in Supplementary Table 3 with their respective q-
values and log2 fold change. Ox., Oxidation; Amm, ammonium ion; M, methionine; A, alanine.
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temperature for 15 min. Total protein and Aβ concentrations were determined by NanoOrange (Molecular 
Probes, Eugene, OR) and ELISA, respectively. 5 ng of total Aβ from each participant sample was dried to com-
pleteness in vacuo. The 2D Clean-Up Kit (GE Healthcare, Piscataway, NJ) was used to desalt and delipidate the 
samples. Precipitated samples were subjected to C8 TopTips (Glygen, Columbia, MD) to separate full-length 
proteins from Aβ peptides (Supplementary Fig. 1, Supplementary Tables 1 and 2). C8 TopTips were conditioned 
in 60% ACN/ 0.05% TFA (w/v) and equilibrated in 0.05% TFA (aq., v/v) three times each for 1 min at 2,000 
rotations-per-minute (rpm). Next, precipitated samples were resuspended in 80 uL of neat formic acid and 
applied to the C8 TopTips and spun for 1 min at 2,000 rpm. The flowthrough was collected and dried to complete-
ness in vacuo and stored at −80 °C until analysis by nLC-MS/MS.
Purification of Insoluble Aβ Aggregates. The pellet of the 100,000 × g spin was resolubilized in 5 M gua-
nidine hydrochloride (pH 8.0) overnight at 4 °C. The resulting guanidine solubilized 100 k pellet was centrifuged 
in a MicroCL 17 R centrifuge at 17,000 × g to remove any guanidine insoluble material. Next, the supernatant was 
diluted 1:10 (0.5 M guanidine, final concentration) in 1X PBS and immunoprecipitated with 100 uL/mL of a 50% 
slurry of immobilized monoclonal antibodies HJ3.4 and HJ5.1 overnight (22 hrs) at 4 °C. Beads were washed 15 
times in 1X PBS (1 mL each) and eluted 3X with 100 uL formic acid at room temperature for 5 min each. Total 
protein and Aβ concentrations were determined by NanoOrange (Molecular Probes, Eugene, OR) and ELISA, 
respectively20. 5 ng of total Aβ from each patient sample was dried to completeness in vacuo. The 2D Clean-Up 
Kit (GE Healthcare, Piscataway, NJ) was used to desalt and delipidate the samples. Precipitated samples were sub-
jected to C8 TopTips (Glygen, Columbia, MD) to separate full-length proteins from Aβ peptides (Supplementary 
Fig. 1, Supplementary Tables 1 and 2). C8 TopTips were condition in 60% ACN/0.05% TFA (v/v) and equilibrated 
in 0.05% TFA (aq., v/v) three times each for 1 min at 2,000 rpm. Next, precipitated samples were resuspended in 
80 uL of neat formic acid and applied to the C8 TopTip and spun for 1 min at 2,000 rpm. The flowthrough was 
collected and dried to completeness in vacuo and stored at −80 °C until analysis by nLC-MS/MS.
Aβ ELISA. The Aβ1-x ELISA was performed as previously described20. Briefly, mouse monoclonal HJ5.1 
(mid-domain) was used to coat 96-well Nunc MaxiSorp plates (464718, Nalge Nunc, Rochester, NY) at 20 μg/
mL in a carbonate buffer (35 mM sodium bicarbonate, 16 mM sodium carbonate, 3 mM sodium azide, pH 9.6) 
using 100 μl/well overnight at 4 °C. After washing 5x and blocking in 2% bovine serum albumin (BSA, A7030, 
Sigma-Aldrich, St. Louis, MO) in 1X PBS for 30 min at room temperature, samples and standards (Aβ1–40 on a 
8-point standard curve) were plated in dilution buffer20 and incubated overnight at 4 °C. Samples and standards 
were developed by incubating in sequence with biotinylated HJ3.4 (canonical N-terminus) at 100 ng/mL for 
1 hour at room temperature, streptavidin HRP-20 (65R-S103PHRP, Fitzgerald, Acton, MA) for 30 min at room 
temperature, and finally 3, 3′, 5, 5′ – tetramethylbenzidine (TME) (T5569, Sigma-Aldrich, St. Louis, MO) for 
measurement on a BioTek Synergy 2 plate reader at 650 nm as previously described20.
Protease Inhibitor Control. While the truncation seen is not likely a post-mortem artifact, we used only 
two protease inhibitors in our homogenization buffer instead of a cocktail of inhibitors, which would protect 
against a broader spectrum of protease activities. To evaluate the possible impact of using only two protease 
inhibitors in the truncation profile of Aβ, we analyzed a representative sample (Pt1) using our standard inhibitors 
(aprotinin and leupeptin) or Halt Protease and Phosphatase Inhibitor Cocktail (78443, Thermo Fisher Scientific) 
at 1X (final concentration). Three grams of frontal tissue was diced (on ice) and split evenly for homogenization 
in either the standard buffer or the cocktail buffer and processed for insoluble and soluble fractions as described 
above (Supplementary Fig. 2). Mass spectrometry analysis we performed as described below. Spider search results 
with a score (−10logP) of 31.7 or higher (an estimated FDR value of 2.3% at the peptide level). Only truncated 
proteoforms were considered for further analysis.
nLC-MS/MS. Samples from each individual CDR3 participant (n = 6, biological replicates) across the HMW 
soluble and insoluble Aβ fractions were split into two technical replicates (of 5 ng total Aβ as measured by ELISA) 
with the exception of Participant 4 (Pt4), which did not have enough material for a second technical replicate. 
All samples were prepared (precipitation and C8 SPE) in two block-randomized sets (https://www.random.org)36 
for each set of participant replicates across two days. Samples were resuspended in 1%/10%/5% FA/ACN/MeOH 
(v/v) and analyzed by non-stop nLC-MS/MS in a block-randomized fashion36 – to eliminate systemic bias due to 
run order – for a total of 22 Thermo.raw files on a LTQ-Orbitrap Fusion (Thermo Fisher Scientific). Throughout 
data acquisition, quality assurance/quality control (QA/QC) standard of 20 fmoles BSA (#P8108S, New England 
BioLabs, Ipswich, MA) was injected every 12–18 hrs to monitor instrument drift and variability over time. 29 BSA 
peptides from each interwoven QA/QC run were analyzed with AutoQC for instrument performance metrics37 
(Supplementary Fig. 3).
Separations were performed using an online NanoAcquity UPLC (Waters). The chromatographic separation 
was performed on an ACQUITY UPLC HSS T3 (360 μm OD × 75 μm ID) column packed with 10 cm C18 (1.8 μm, 
100 Å, Waters) at 300 nL/min and heated to 60 °C. Mobile phases were 0.1% FA in water (A) and 0.1% FA in ACN 
(B). Samples were eluted from the column with the gradient ramped to 35% B over 65 min and further increased 
to 95% B over 8 min and held for an additional 6 min. Total run time, including column equilibration, sample 
loading, and analysis was 89 min. The mass spectrometer was operated in data-dependent mode to automati-
cally switch between MS and MS/MS acquisition. The survey scans at mass-charge ratio (m/z) 400–2000 (MS) 
were acquired in the Orbitrap at high resolution (60,000 at m/z 400) in profile mode, and the MS/MS spectra 
were acquired in the Orbitrap (15,000 at m/z 400) in centroid mode using XCalibur, version 3.0 (Thermo Fisher 
Scientific). Ion injection times for the MS and MS/MS scans were 500 ms each. The automatic gain control targets 
were set as 2 × 105 for MS and MS/MS in the Orbitrap. The most abundant precursor ions from each MS scan 
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were sequentially isolated and fragmented in the Orbitrap using HCD (isolation width 2.0 Da, normalized col-
lision energy 30%, activation Q 0.250, and activation time 10 ms) within a 3 sec duty cycle (TopSpeed method). 
Dynamic exclusion (±10 ppm relative to precursor ion m/z) was enabled with a repeat count of one, a maximal 
exclusion list size of 500, and an exclusion duration of 60 s. Monoisotopic precursor selection (MIPS) was enabled 
and unassigned ions were rejected.
Mass Spectrometry Data Processing. MS files (.raw) were imported into PEAKS (version 8, 
Bioinformatics Solutions Inc., Waterloo, ON) and searched against a UniprotKB/SwissProt Human database of 
reviewed, canonical sequences (October 2015; 20,204 entries) appended with the cRAP contaminant database 
(January 2015 version, The Global Proteome Machine, www.thegpm.org/cRAP/index.html). Precursor ion mass 
tolerance was set to 10 ppm, and fragment mass tolerance was 0.1 Da with no enzyme specificity. All modifica-
tions in the UniMod database (http://www.unimod.org) were considered in the PEAKS search. PEAKS auto-
matically generates a decoy-fusion database, which appends a decoy sequence to each protein identification for 
the calculation of FDR38. The Spider search results with a score (−10logP) of 31.9 or higher (an estimated FDR 
value of 2.9% at the peptide level) for the CDR3 cohort data. Spider is an algorithm tool within PEAKS, which 
we utilized to search peptide spectrum matches not identified by the database search by altering the amino acids 
systematically at each residue until a new, better peptide sequence is constructed from the MS/MS data39. All 
non-Aβ peptides and those Aβ proteoforms containing formylation were removed. Immunoprecipitation elution 
was in neat formic acid (Sigma #94318); thus, formylation occurring endogenously or by the elution conditions 
is indistinguishable. Further, samples were resuspended in MS buffer containing 5% methanol (v/v) to maintain 
solubility of Aβ, which in combination with 1% FA could lead to artefactual methylation via Fischer esterification.
In the CDR3 cohort, 27 Aβ proteoforms were identified meeting the criteria described above. However, we 
sought reproducible identification of the 27 Aβ proteoforms on an independent platform. The filtered list of Aβ 
proteoforms were i) assigned identification numbers by a third party who had no part in the initial analysis and 
ii) transformed into chemical formulas. This chemical formula list was queried against each.raw file with National 
Resource for Top-Down Proteomics (NRTDP) pipeline version 1.3 at ± 10 ppm precursor ion mass tolerance and 
a 4 min retention time window alignment (Supplementary Fig. 4). If a given proteoform was not identified by 
both platforms (PEAKS and NRTDP), it was removed from analysis; 26 out of 27 were reproducibly identified on 
both platforms. MS intensity was calculated across all peaks within an isotopic cluster extracted with Skyline for 
each proteoform identified in Fig. 2 and exported as an Excel file.
Differential Mass Spectrometry (dMS). In this method relative quantitation is performed from the 
full-scan MS. The high-resolution MS provides m/z, retention time, charge state, and relative abundance (inten-
sity) of precursor ion across multiple samples for comparative analysis40–43. A table of proteoform intensities was 
imported into a custom SAS script for analysis. To detect differential (label-free) abundance from the intensities 
data40, the MS intensity measures (calculated as described above) for each proteoform were standardized to 
Z-scores across all measures of that proteoform. Different charge states were treated as independent measures of 
the same proteoform as reflected in the increased degrees of freedom for certain tests (Supplementary Table 3).
ANOVA based on a hierarchical linear model (HLM) with replicates nested within patients, and patients 
treated as random effects, was used to test the fixed effect difference between soluble aggregate Aβ and more 
insoluble Aβ fractions. All calculations were done using SAS PROC MIXED with restricted maximum likeli-
hood estimations (SAS Institute, Cary, NC) and type 3 sums of squares (where appropriate). The HLM was used 
to test for differences in mean intensity between CDR3 soluble and insoluble Aβ fractions, while allowing each 
biological replicate to have its own overall mean. Each p-value of the resulting 26 F tests was corrected for mul-
tiple testing (q-value), and those with an FDR of ≤0.05 were considered significant44. Next, the same model was 
run on the log2-converted raw intensities. The difference in estimated mean between aggregate Aβ and more 
insoluble Aβ fractions in these tests was taken as an estimate of the overall fold change within the fractions. Thus 
two separate ANOVA analyses are run, the first to test the statistical significance of abundances of proteoforms 
between fractions, and the second to estimate effect size25, 45. The mass spectrometric data have been deposited in 
ProteomeXchange (http://proteomecentral.proteomexchange.org) via the PRIDE partner repository46 with the 
data set identifier PXD005119.
Data Visualization. Analyses were performed and visualized with Excel 2013, PRISM (version 7) for corre-
lation analysis of signal intensity and PMI and graphing volcano plots or SAS (version 9.4) for hierarchical linear 
modeling.
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